Wall Street analysts predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will announce ($1.03) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Atara Biotherapeutics’ earnings. The lowest EPS estimate is ($1.10) and the highest is ($0.95). Atara Biotherapeutics reported earnings of ($0.88) per share during the same quarter last year, which indicates a negative year over year growth rate of 17%. The firm is scheduled to report its next earnings report on Friday, November 3rd.

On average, analysts expect that Atara Biotherapeutics will report full-year earnings of ($4.00) per share for the current financial year, with EPS estimates ranging from ($4.24) to ($3.75). For the next financial year, analysts forecast that the firm will report earnings of ($4.60) per share, with EPS estimates ranging from ($5.25) to ($3.94). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05.

ATRA has been the topic of several research analyst reports. Jefferies Group LLC restated a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, August 31st. William Blair restated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 target price on the stock in a research report on Tuesday, August 22nd. ValuEngine upgraded shares of Atara Biotherapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research report on Monday, August 7th. Four analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $23.60.

Atara Biotherapeutics (NASDAQ ATRA) opened at 15.10 on Monday. The firm’s market capitalization is $461.44 million. Atara Biotherapeutics has a 52-week low of $11.80 and a 52-week high of $23.00. The firm’s 50-day moving average is $14.83 and its 200-day moving average is $15.87.

ILLEGAL ACTIVITY NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/09/07/1-03-eps-expected-for-atara-biotherapeutics-inc-atra-this-quarter.html.

In other news, EVP Christopher Haqq sold 6,000 shares of Atara Biotherapeutics stock in a transaction on Monday, July 17th. The stock was sold at an average price of $14.92, for a total transaction of $89,520.00. Following the completion of the transaction, the executive vice president now owns 362,080 shares of the company’s stock, valued at approximately $5,402,233.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $13.54, for a total value of $59,576.00. Following the transaction, the chief executive officer now directly owns 737,767 shares of the company’s stock, valued at approximately $9,989,365.18. The disclosure for this sale can be found here. Insiders have sold a total of 46,109 shares of company stock valued at $673,304 in the last ninety days. Corporate insiders own 16.10% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its stake in shares of Atara Biotherapeutics by 2.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after buying an additional 610 shares during the last quarter. American International Group Inc. raised its stake in shares of Atara Biotherapeutics by 7.1% during the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Atara Biotherapeutics by 2.4% during the 2nd quarter. Teachers Advisors LLC now owns 47,156 shares of the biotechnology company’s stock worth $660,000 after buying an additional 1,110 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Atara Biotherapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after buying an additional 1,369 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Atara Biotherapeutics by 5.8% during the 2nd quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock worth $368,000 after buying an additional 1,445 shares during the last quarter. 82.95% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.